Cancer War

Oncotarget Aims to Treat Drug-Resistant Breast Cancer Baker

Researchers at Oncotarget have discovered a potential way to make treatment more effective in an aggressive type of breast cancer that effects 15 percent of patients known as triple negative breast cancer (TNBC). Currently, hormone based therapy is essentially ineffective in TNBC as the cancerous cells lack the hormone receptors [ » ]

Oncotarget Aims to Treat Drug-Resistant Breast Cancer